| 期 |
栏目 |
标题 |
文件 |
| 卷 90, 编号 7 (2018) |
Editorial |
Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice |
(Rus)
|
| 卷 91, 编号 7 (2019) |
Editorial |
Epidemiology of multiple myeloma in city Moscow |
(Rus)
|
| 卷 92, 编号 7 (2020) |
Original articles |
Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy |
(Rus)
|
| 卷 93, 编号 4 (2021) |
Original articles |
Analysis of the effectiveness of multiple myeloma treatment based on the clinical experience of European countries |
(Rus)
|
| 卷 93, 编号 7 (2021) |
Original articles |
Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice |
(Rus)
|
| 卷 93, 编号 7 (2021) |
Original articles |
Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience |
(Rus)
|
| 卷 93, 编号 11 (2021) |
Original articles |
The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial |
(Rus)
|
| 卷 94, 编号 7 (2022) |
Original articles |
Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT) |
(Rus)
|
